ModifiedUnitedHealthcarePolicy CS16SNJ.F

Genetic Testing for Neuromuscular Disorders (for New Jersey Only)

This policy governs coverage and clinical criteria for multi-gene genetic testing (panels of five or more genes) for suspected neuromuscular disorders for UnitedHealthcare members in New Jersey.

Policy Summary

PayerUnitedHealthcare

PolicyGenetic Testing for Neuromuscular Disorders (for New Jersey Only)

Policy CodePolicy CS16SNJ.F

Change TypeClarified noncoverage of multi-condition comprehensive panelssupporting sections updated

Effective DateOct 1, 2024

Next Review DateN/A

Key ActionDocument clinical phenotype, prior testing results, and rationale when ordering multi-gene panels; verify state/contract benefit rules and obtain specialist/genetics consultation when indicated.

SourceLink

POLICY UPDATE CHANGES

Added language to clarify multi-gene comprehensive neuromuscular disease test panels targeting multiple conditions (e.g., muscular dystrophy and mitochondrial disease) are unproven and not medically necessary.

Updated Description of Services, Clinical Evidence, and References sections to reflect current information.

5+Minimum genes for covered multi-gene panels

NJPolicy application state

1Explicit major policy change called out in history

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Multi-Gene Neuromuscular Panels

inv-01: Covered when ALL of the following are met

Multi-gene targeted panel testing (five or more genes) is medically necessary when ALL of the following are met:

Covered Indications - general: Panel testing of five or more genes is medically necessary for suspected hereditary ataxia; congenital myopathy, distal myopathy, metabolic myopathy (e.g., glycogen storage disease), myofibrillar myopathy; hereditary peripheral neuropathy; muscular dystrophy (including limb girdle and congenital forms); hereditary spastic paraplegia; or mitochondrial diseases (e.g., Kearns-Sayre syndrome, LHON, Leigh, MELAS) when clinical criteria are met.Panels must include 5 or more genes

See mitochondrial-specific subcriteria

Mitochondrial disease subcriteria: For mitochondrial disease panels, all of the following must be met: high degree of suspicion based on medical or family history, laboratory or clinical tests; testing ordered by or in consultation with a board-certified medical geneticist, developmental pediatrician, or neurologist; the clinical presentation does not support single-gene or targeted analysis; and clinical features consistent with mitochondrial disease (examples: proximal weakness; progressive external ophthalmoplegia; muscle cramping, fatigue, or exercise intolerance; sensorineural hearing loss).

From Coverage Rationale; MMS guidance

inv-02: Not medically necessary

Not medically necessary: Multi-gene comprehensive neuromuscular disease test panels that target multiple distinct neuromuscular conditions concurrently (for example, panels combining muscular dystrophy and mitochondrial disease targets) are considered unproven and not medically necessary due to insufficient evidence of efficacy.

Declared in Instructions for Use and Policy History; explicit exclusion for multi-condition panels

inv-03: Supported testing indications

Covered when testing is clinically indicated based on phenotype and/or prior diagnostic testing

Glycogen storage disease (GSD) evaluation: Genetic testing (targeted gene testing or NGS panel) is supported when biochemical or enzymatic testing (e.g., GAA enzyme assay for Pompe) or muscle biopsy/forearm exercise test suggests a specific GSD, or when clinical presentation (proximal weakness, elevated CK, exercise intolerance, second‑wind phenomenon for McArdle) warrants differentiation among GSDs.

Supported by Lantern Project, Levesque et al., and other studies

Fatty acid oxidation (FAO) disorders: Coverage supported when metabolic testing (acylcarnitine profile by mass spectrometry) suggests an FAO disorder or when clinical features such as rhabdomyolysis or hypoketotic hypoglycemia are present; targeted genetic testing to confirm biochemical findings is appropriate, with broader panels or exome/genome considered if targeted testing is negative or phenotype is unexpected.

Acylcarnitine testing can be false negative if performed during non‑stressed periods

Hereditary ataxia and IPN testing: Use of targeted NGS panels or clinical exome is supported when individuals have a phenotype suggestive of hereditary disease (family history, early onset, or specific clinical features) or when recommended first‑tier tests are negative; diagnostic yields vary by cohort and guide phenotype‑driven testing.

inv-04: Not routinely supported

Not routinely covered

Cryptogenic polyneuropathy without hereditary phenotype: Routine genetic testing is not supported for individuals with cryptogenic polyneuropathy who do not have a classical hereditary phenotype or supporting electrodiagnostic or family history findings.

Consistent with AAN/AANEM guidance; low yield without a hereditary phenotype

inv-05: Clinical-phenotype driven testing and escalation

Covered when testing selection is guided by clinical phenotype and prior diagnostic workup

Phenotype and testing pathway: Targeted genetic testing for specific CMD/LGMD subtypes may be ordered when phenotype and/or histology indicate a specific molecular cause; use muscle biopsy findings, EMG, CK, and cardiac/respiratory evaluation to narrow differential and guide testing selection.

AAN/AANEM guidance recommends targeted testing when phenotype is well characterized

Escalation to broader testing: When targeted testing is negative or phenotype is not attributable to a well‑characterized gene, clinicians may escalate to whole‑exome or whole‑genome sequencing or broader NGS panels based on specialty consultation and institutional factors.

Suggested by AAN/AANEM and study guidance as second‑line

inv-06: Situations with insufficient evidence

Not routinely covered/low-yield situations

Cryptogenic polyneuropathy: Routine genetic testing is unsupported for individuals with cryptogenic polyneuropathy in the absence of a classical hereditary phenotype, as evidence does not support routine use.

Authors concluded insufficient evidence for routine testing

inv-07: Phenotype-directed single-gene or small-panel testing

Phenotype-directed gene testing — covered when testing matches specific clinical features

Phenotype-directed testing examples: Order single‑gene testing or small panels when specific phenotype features point to a particular gene: e.g., FKRP for scapular winging/calf hypertrophy/early cardiorespiratory involvement; PLEC for epidermolysis bullosa or pyloric atresia; POMT1/POMT2/ISPD/FKTN/FKRP/LARGE1/POMGNT1 for dystroglycanopathy features with intellectual disability; DMD testing for suspected dystrophinopathy; a‑glucosidase (Pompe) dried blood spot when biopsy uninformative.

AAN/AANEM phenotype–genotype recommendations

inv-08: Inheritance-pattern testing rules

Inheritance and phenotype-specific guidance

X-linked or sex-specific testing: For probable X‑linked limb‑girdle patterns: in females test DMD or perform dystrophin immunostaining on muscle biopsy to assess mosaicism; in males test DMD gene directly.

AAN/AANEM recommendations

Humeroperoneal pattern guidance: For humeroperoneal weakness: if joint laxity and protuberant calcaneus without cardiac involvement test collagen VI genes; if early cardiac involvement without joint laxity test LMNA; for congenital onset with laxity test collagen VI (Ullrich); for X‑linked humeroperoneal test EMD when protuberant calcaneus and no cardiac involvement.

Phenotype‑directed inheritance guidance per AAN/AANEM

inv-09: Algorithm for nondiagnostic initial testing

When initial testing is nondiagnostic

Escalation to biopsy and broad sequencing: If initial genetic testing, muscle biopsy, and Pompe dried blood spot are nondiagnostic, obtain genetic consultation and consider parallel sequencing approaches — targeted exomes, WES, WGS, or broad NGS panels — to identify a genetic abnormality.

AAN/AANEM recommend escalation to broader sequencing when initial workup non‑diagnostic

Panel then WES approach: Many centers use targeted NGS panels of mitochondrial and nuclear genes first; WES can follow negative panels in selected patients (guided by family history, consanguinity, and availability of family members) to increase diagnostic yield.

Reported approaches in clinical series (Legati et al.)

inv-10: Mitochondrial testing criteria

Mitochondrial testing-specific criteria

Preferred mtDNA methodology: Massively parallel sequencing/NGS of the entire mtDNA genome is preferred over testing for a limited set of pathogenic point mutations.

MMS recommendation

Tissue-based testing when indicated: If there is a strong likelihood of an mtDNA mutation and blood testing is negative, perform mtDNA testing on another tissue (e.g., muscle or urine); consider urine heteroplasmy analysis (for example, MELAS m.3243A>G) and mtDNA copy number testing by qPCR for depletion when tissue is obtained.

MMS guidance to avoid missed tissue‑specific mutations and to assess heteroplasmy/depletion

Nuclear gene sequencing when multiple deletions: When multiple mtDNA deletions are observed, sequence nuclear genes involved in mtDNA biosynthesis; use NGS panels with complete coverage for nuclear‑encoded mitochondrial disease genes and avoid single‑gene testing when possible.

MMS recommendation to prefer NGS panels or WES over single‑gene testing

inv-11: Not medically necessary — multi-condition comprehensive panels

Policy history and instructions summarize coverage stance and implementation notes.

Primary coverage stance: Multi‑gene comprehensive neuromuscular disease test panels that concurrently target multiple distinct neuromuscular conditions (for example, combining muscular dystrophy and mitochondrial disease targets) are considered unproven and not medically necessary and therefore are not covered when submitted as such.

Stated in Policy History and Instructions for Use

This policy defines coverage for multi-gene targeted panel testing consisting of panels with 5 or more genes for suspected neuromuscular disorders when clinical criteria are met. The policy also clarifies that multi-gene comprehensive neuromuscular disease test panels that target multiple distinct conditions (for example, muscular dystrophy combined with mitochondrial disease) are considered unproven and not medically necessary due to insufficient evidence. Use the condition-specific criteria and mitochondrial subcriteria to determine when multi-gene panel testing is appropriate.

Routine genetic testing is not supported for individuals with cryptogenic polyneuropathy who lack a classical hereditary phenotype. Guidelines recommend a stepwise, phenotype-driven approach with first-tier laboratory and electrodiagnostic testing (for example, PMP22 duplication testing when indicated) and targeted gene testing guided by inheritance pattern and clinical features before broader NGS panels are considered.

Reiterating guideline-based guidance: when cryptogenic polyneuropathy does not exhibit features of hereditary neuropathy (family history, characteristic electrodiagnostic findings), routine broad genetic testing is low yield and therefore generally not medically necessary without phenotype-directed justification and appropriate prior testing.

For individuals with likely primary mitochondrial disease, reliance on single-gene testing is discouraged. The policy and Mitochondrial Medicine Society guidance recommend NGS/massively parallel sequencing of the entire mtDNA genome and comprehensive NGS nuclear gene panels with complete coverage; single-gene testing should usually be avoided because different genes can produce similar phenotypes.

When multi-gene panels are used, they should be phenotype-directed and clinically justified. Targeted NGS panels (including CNV analysis) are supported for well-characterized CMD, LGMD, IPN, and other neuromuscular phenotypes; if targeted testing is nondiagnostic, escalation to broader sequencing such as WES/WGS may be appropriate following specialist consultation and documentation of prior workup.

Multi-gene panels that concurrently target multiple distinct neuromuscular disease categories (for example, a single panel designed to detect both muscular dystrophy and mitochondrial disease targets) are considered unproven and not medically necessary and therefore are excluded from coverage when submitted as such.

Ordering broad genetic testing without first performing an appropriate phenotype-directed evaluation (including recommended first-tier biochemical, electrodiagnostic, or targeted tests) is discouraged. Failure to document a hereditary phenotype or prior tiered testing may place the claim at risk for denial.

Restating the policy stance: claims for multi-gene comprehensive neuromuscular disease test panels targeting multiple conditions (e.g., combining muscular dystrophy and mitochondrial disease in one panel) are considered not medically necessary because evidence of clinical utility for such multi-condition panels is insufficient.

Indications Supported for Coverage

inv-57: Suspected hereditary neuromuscular disorders (list of conditions) — panels must be multi-gene (5+ genes) and clinically justified

Suspected neuromuscular conditions appropriate for clinically justified multi‑gene (≥5 gene) panels:

List of suspected hereditary neuromuscular disorders: Suspected hereditary ataxia; congenital myopathy; distal myopathy; metabolic myopathy (e.g., glycogen storage diseases such as Pompe); myofibrillar myopathy; hereditary peripheral neuropathy (including CMT/IPN); muscular dystrophy (including limb‑girdle and congenital forms); hereditary spastic paraplegia; or mitochondrial diseases (e.g., KSS, LHON, Leigh, MELAS). Multi‑gene panels must include five or more genes and be clinically justified by phenotype and prior workup.Panels must include 5 or more genes

Coverage Rationale and Covered Indications

inv-58: Clinical features or biochemical tests suggesting specific neuromuscular genetic disease (examples and rationale)

Clinical features or biochemical tests that suggest specific neuromuscular genetic diseases include, but are not limited to:

Member and Test Eligibility Notes

No eligibility requirements are specified in the extracted sections for top-level family-history or other single-node eligibility rules.

No additional top-level eligibility criteria are listed in this policy excerpt.

This policy does not provide discrete eligibility nodes in the extracted content for automated eligibility determination.

No eligibility criteria available in this section.

No top-level eligibility requirements are present in the provided excerpts.

No eligibility criteria are defined in these extracted sections.

No eligibility requirements specified in the extracted policy material.

No eligibility information available for this block in the provided document excerpts.

Provider Actions, Documentation, and Prior Authorization Guidance

Documentation Required

Provider Action: Provide clinical justification and prior workup

Provide clear clinical justification and prior workup when ordering multi-gene NMD or mitochondrial testing. Include the suspected phenotype, detailed history (onset, progression, exercise tolerance), family history/pedigree, specialty evaluations (neurology/genetics), targeted prior testing results (single-gene tests, enzymatic assays, MLPA/duplication testing, mtDNA testing in blood and other tissues when indicated), and relevant laboratory/histology (CK, EMG, muscle biopsy findings, lactic acid/ammonia exercise testing, GAA enzyme activity if Pompe suspected). Documentation should explicitly support the choice of a multi-gene panel versus targeted single-gene testing or tissue-based testing.

Document phenotype (pattern of weakness, cardiopulmonary involvement, age of onset).
Include prior targeted tests and results (e.g., PMP22 duplication testing, GAA enzyme assay, mtDNA blood testing).
Attach muscle biopsy, EMG, CK, and biochemical test results when available.
Note specialist involvement: neurologist, neuromuscular clinic, or board-certified medical geneticist.

Coding and Billing

Listed molecular/PLA/CPT codes (reference)mixed

0216U	Neurology (inherited ataxias), genomic DNA sequence analysis of 12 common genes including small sequence changes, deletions, duplications, short tandem repeat expansions, and variants in non-uniquely mappable regions; blood or saliva.
0217U	Neurology (inherited ataxias), genomic DNA sequence analysis of 51 genes including small sequence changes, deletions, duplications, short tandem repeat expansions, and variants in non-uniquely mappable regions; blood or saliva.
0417U	Whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis; nuclear-encoded mitochondrial gene analysis of 335 nuclear genes, including sequence changes, deletions, insertions, and copy number variants; blood or saliva.
81440	Nuclear encoded mitochondrial genes genomic analysis (examples listed: COX10, DGUOK, MPV17, OPA1, PDSS2, POLG, POLG2, RRM2B, SCO1, SCO2, SLC25A4).

Additional molecular/CPT codesmixed

81448	Hereditary peripheral neuropathies (e.g., Charcot-Marie-Tooth; spastic paraplegia), genomic sequence analysis panel; must include sequencing of at least 5 peripheral neuropathy–related genes.
81460	Genomic sequence analysis that must include sequence analysis of the entire mitochondrial genome with heteroplasmy detection (associated mitochondrial disorder indications such as MELAS, MERRF, NARP, LHON).
81465	Includes heteroplasmy detection, if performed (unlisted molecular pathology procedure description associated with mitochondrial testing).

Minimum panel size (definition)

Minimum panel sizePanels must include 5 or more genes to meet the multi-gene panel definition in this policy.

Policy contextMulti-gene targeted panel testing (5 or more genes) is the defined covered panel type for suspected neuromuscular disorders.

Coding noteApplicable panel CPT/PLA codes reference panels that must include sequencing of at least 5 related genes (see CPT code descriptors).

Tests and Situations Not Covered

Multi-gene comprehensive neuromuscular disease test panels that target multiple distinct conditions (for example, combining muscular dystrophy and mitochondrial disease targets into a single panel) are explicitly listed as not covered in the policy. This reflects an evidence-based determination that such broad, multi-condition panels are unproven and not medically necessary.

Routine genetic testing for cryptogenic polyneuropathy without a classical hereditary phenotype is considered not covered. Guidelines advise phenotype-directed testing and recommend first-tier laboratory and electrodiagnostic evaluations before genetic testing is pursued.

Evidence is insufficient to support routine genetic testing in cryptogenic polyneuropathy lacking a characteristic hereditary phenotype; therefore such testing is generally not covered unless clinical features and prior workup indicate otherwise.

Reliance on single-gene testing for cases likely representing primary mitochondrial disease is discouraged and considered not covered when it replaces recommended comprehensive mtDNA and nuclear gene NGS approaches. Best practices favor NGS of the complete mtDNA genome and comprehensive nuclear gene panels, with tissue-based testing when blood is negative.

Again, multi-gene panels that indiscriminately combine tests for multiple neuromuscular disease categories are stated as not covered because of insufficient evidence supporting their clinical utility.

Definitions and Terminology

Comparative Genomic Hybridization (CGH)

TermComparative Genomic Hybridization (CGH)

DefinitionA technology used to detect genomic copy number variations (CNVs) using probes or single nucleotide polymorphisms to compare patient and reference DNA; patient and reference DNA are labeled and hybridized to an array and differences in probe intensity indicate copy-number changes.

Use in NMD testingCGH is used to detect deletions/duplications and other CNVs that may underlie neuromuscular disorders.

Next Generation Sequencing (NGS)

TermNext Generation Sequencing (NGS)

DefinitionHigh-throughput DNA sequencing of large numbers of genes in a single reaction (massively parallel sequencing), enabling multi-gene panels, mtDNA genome sequencing, and detection of heteroplasmy.

Background and Evidence Summary

Neuromuscular disorders are a heterogeneous group of inherited conditions affecting muscle function or the nerves innervating muscle. Common presentations include muscle weakness, exercise intolerance, elevated creatine kinase, and respiratory or cardiac involvement. Genetic testing options range from single-gene assays to multi-gene NGS panels, CGH/array, and exome/genome sequencing; multi-gene NGS panels of 5 or more genes can assist diagnosis, prognosis, and management when chosen based on clinical phenotype and prior diagnostic testing.

Policy Revision History

2024-10-01policy_revisionLatest

Added language clarifying that multi-gene comprehensive neuromuscular disease test panels targeting multiple conditions (e.g., muscular dystrophy and mitochondrial disease) are unproven and not medically necessary.

Policy Summary

PayerUnitedHealthcare

PolicyGenetic Testing for Neuromuscular Disorders (for New Jersey Only)

Policy CodePolicy CS16SNJ.F

Change TypeClarified noncoverage of multi-condition comprehensive panelssupporting sections updated

Effective DateOct 1, 2024

Next Review DateN/A

SourceLink

On This Page

Guideline recommends phenotype‑guided, stepwise testing to increase yield

Examples of clinical features/biochemical tests:

Findings such as abnormal GAA enzyme activity or supportive GAA sequencing for Pompe disease; forearm exercise test or muscle biopsy findings suggestive of McArdle disease; abnormal acylcarnitine profile by mass spectrometry suggesting FAO disorders; phenotype consistent with CMT/IPN (distal symmetric weakness, sensory loss, electrodiagnostic classification); early‑onset hereditary ataxia or family history suggestive of inherited ataxia. These findings can justify targeted genetic testing or panel testing when phenotype overlaps or single‑gene testing is unrevealing.

Levesque, Lantern Project, Houten, Antoniadi studies support phenotype‑directed testing

inv-59: Individuals with clinical features of CMD, LGMD, MFM, or other suspected inherited neuromuscular disorders where phenotype, biopsy, or family history point to genetic etiology

Individuals for whom targeted NGS panels, CNV analysis, or WES are supported when phenotype, biopsy, or family history point to a genetic etiology:

CMD/LGMD/MFM and other suspected inherited neuromuscular disorders: Individuals with clinical features of congenital muscular dystrophy (CMD), limb‑girdle muscular dystrophy (LGMD), myofibrillar myopathy (MFM), or other suspected inherited neuromuscular disorders where phenotype, muscle biopsy findings, and/or family history indicate a genetic cause are candidates for targeted NGS panels (with CNV analysis) or WES as clinically indicated.

O'Grady et al., Lantern Project, Winckler studies demonstrate diagnostic yield

inv-60: Phenotype-directed testing examples for muscular dystrophies and neuromuscular disorders

Phenotype-directed testing examples to guide selection of single genes or small panels:

Muscular dystrophy and neuromuscular disorder examples: Examples include testing FKRP for scapular winging, calf hypertrophy, and early cardiorespiratory involvement; PLEC for epidermolysis bullosa or pyloric atresia presentations; DMD testing for suspected dystrophinopathy (sex‑specific guidance applies); collagen VI gene testing for humeroperoneal patterns with joint laxity; LMNA testing for early cardiac involvement; testing anoctamin‑5 or dysferlin for early onset calf weakness; and performing a dried blood spot a‑glucosidase assay for Pompe disease when biopsy is uninformative. When initial tests are nondiagnostic, consider genetic consultation and escalation to broader sequencing.

AAN/AANEM phenotype–genotype recommendations and escalation guidance

inv-61: Suspected mitochondrial disease — mtDNA sequencing, nuclear gene panels, tissue testing when blood negative

Suspected mitochondrial disease testing approach and tissue considerations:

mtDNA genome and nuclear panel testing: NGS sequencing of the entire mtDNA genome and targeted nuclear gene panels for mitochondrial disease are supported when clinical suspicion is high.

MMS recommends NGS of mtDNA and nuclear panels

Tissue testing when blood is negative: If blood mtDNA testing is negative despite strong clinical suspicion, perform mtDNA testing on another tissue (e.g., muscle, urine) to detect tissue‑specific heteroplasmy; consider mtDNA deletion/duplication testing and mtDNA copy number (depletion) testing by qPCR on tissue specimens when obtained.

MMS guidance to avoid missed diagnoses due to heteroplasmy and depletion

Nuclear gene sequencing after multiple deletions or negative mtDNA: When multiple mtDNA deletions are observed or when nuclear causes are suspected, perform NGS nuclear gene panels with complete coverage and avoid reliance on single‑gene testing; consider WES when panels are non‑diagnostic.

MMS recommendations

Prior Authorization

Provider Action: Prior authorization guidance for NGS

Prior authorization may be required for NGS-based multi-gene panels, whole exome, or whole genome testing. When requesting authorization, include documentation of prior targeted testing and rationale for choosing a panel or WES/WGS (why single-gene or smaller panel is insufficient). Specify whether mtDNA testing was performed on blood and, if negative but clinical suspicion remains, whether tissue-based mtDNA testing is planned or performed.

Reference applicable CPT/PLA codes on the request and confirm coverage/prior authorization requirements with UnitedHealthcare before testing.
For NGS panels, provide justification for panel size and gene content relative to the suspected phenotype.
If WES/WGS is requested, document nondiagnostic prior targeted testing and multidisciplinary/genetics consultation.

Note

Provider Action: Verify benefit-specific requirements

Verify benefit-specific requirements prior to ordering. Coverage may differ by federal, state, or contractual terms; check the member's plan and any state/federal mandates that may affect coverage.

Confirm the member's federal/state/contractual plan terms to determine applicability of this policy.
In case of conflict, applicable federal, state, or contractual requirements govern coverage decisions.
Use UnitedHealthcare tools or third-party criteria (e.g., InterQual) as applicable for benefit administration.

Denial Risk

Provider Action: Phenotype not consistent with hereditary disease

Testing is unsupported when the phenotype is not consistent with a hereditary neuromuscular disorder. Do not order broad genetic panels solely for cryptogenic presentations without a classical hereditary phenotype and without first performing recommended first-tier evaluations.

Insufficient evidence to support routine genetic testing for cryptogenic polyneuropathy without classical hereditary features.
Provide electrodiagnostic, family history, or other phenotype-directed evidence before panel testing.

Denial Risk

Provider Action: Failure to perform tissue-based mtDNA testing when indicated may affect coverage

For suspected mitochondrial disease, failure to perform tissue-based mtDNA testing when indicated may affect coverage. If blood mtDNA testing is negative but clinical suspicion remains, document plans for or results from testing in affected tissue (e.g., muscle) or urine heteroplasmy analysis as appropriate.

mtDNA testing in blood may miss tissue-specific mutations or low heteroplasmy; obtain tissue testing when clinically indicated.
Document rationale for tissue selection and include heteroplasmy results when available.
Ordering should be done by or in consultation with genetics specialists or experienced mitochondrial clinicians.

Documentation Required

Provider Action: Clinical documentation supporting panel choice

Clinical documentation must support the choice of a multi-gene panel. Use targeted single-gene/smaller-panel testing when the phenotype or specific tests (biochemical/enzyme assays, biopsy) point to a limited differential. Multi-gene panels are appropriate when phenotype is heterogeneous or prior targeted testing is nondiagnostic.

Explain why single-gene testing is insufficient and how the panel content maps to the suspected phenotype.
Include prior workup that narrows differential but leaves multiple candidate genes.
Avoid ordering comprehensive multi-condition panels that combine unrelated neuromuscular conditions without clear rationale.

Documentation Required

Provider Action: Required clinical and laboratory documentation

Required clinical and laboratory documentation should be submitted with the testing request: clinical features, biochemical/enzyme testing, prior targeted genetic tests (including MLPA/duplication testing), muscle biopsy results, EMG, CK levels, and specialist consultation notes.

Provide specific prior test names and dates (e.g., PMP22 duplication testing, GAA enzyme assay by TMS).
Include muscle biopsy histology/immunohistochemistry or immunoblot results when available.
Attach relevant lab values (CK, lactic acid, ammonia) and exercise test results if metabolic myopathy suspected.

Documentation Required

Provider Action: Clinical evaluation to support testing

Clinical evaluation should be used to narrow the differential before broad panel testing. Pattern of weakness, presence of cardiopulmonary involvement, EMG findings, CK levels, and muscle biopsy can focus testing to the most likely genes or guide the need for broader analysis.

Refer to specialized neuromuscular centers when possible for multidisciplinary evaluation.
Use EMG/nerve conduction studies and biopsy findings to prioritize specific gene tests or panels.
Document cardiac and respiratory assessments when relevant to the suspected disorder.

Documentation Required

Provider Action: Clinical documentation to support testing

Provide comprehensive clinical documentation to support testing requests, including detailed history, specialty referral notes, and prior biochemical or histologic testing. This supports selection of panel versus WES/WGS and helps reduce the risk of denial.

Include referrals or consultation notes from neurologists, geneticists, or mitochondrial specialists.
State explicitly why broader sequencing is necessary after prior targeted approaches were nondiagnostic.
When requesting WES/WGS, include evidence of multidisciplinary review or genetics consultation.

Step Therapy

Provider Action: Stepwise and tiered testing approach

Stepwise and tiered testing approaches are preferred. Perform first-tier biochemical, enzymatic, and targeted genetic tests guided by phenotype (examples: PMP22 duplication testing for demyelinating CMT phenotype; GAA enzyme assay and sequencing for suspected Pompe disease; mtDNA sequencing in blood and tissue for suspected mitochondrial disease). Reserve broad NGS panels or WES/WGS when initial targeted testing is nondiagnostic or phenotype remains unclear.

Follow published guideline tiered algorithms (e.g., AAN/AANEM recommendations for CMT and LGMD).
Targeted testing first for well-characterized congenital myopathy (CMD) subtypes; WES/WGS when nondiagnostic.
For mitochondrial evaluation: mtDNA testing first (blood), then nuclear gene panel, and reserve WES/WGS for unresolved cases.

Note

Provider Action: Reference contractual/federal/state benefit terms

Reference contractual, federal, and state benefit terms when making coverage decisions. This policy guides interpretation of UnitedHealthcare standard benefit plans but does not override specific plan or regulatory requirements.

In case of conflict between this policy and specific federal/state/contractual requirements, those requirements govern.
Confirm member-specific coverage prior to ordering and obtain any required prior authorizations.

RolePreferred methodology for mtDNA genome sequencing and for targeted nuclear gene panels in suspected neuromuscular and mitochondrial disease.

Variant of Unknown Significance (VUS)

TermVariant of Unknown Significance (VUS)

DefinitionA variation in a genetic sequence that has an unknown association with disease; may also be called an unclassified variant.

ImplicationVUS results require cautious interpretation and often further family or functional studies for clarification.

Whole Exome Sequencing (WES)

TermWhole Exome Sequencing (WES)

DefinitionA DNA analysis technique that sequences all exons (protein-coding regions) of the genome simultaneously rather than gene-by-gene.

RoleWES is a recommended escalation after nondiagnostic targeted testing or when phenotype/family history justifies broader analysis.

Whole Genome Sequencing (WGS)

TermWhole Genome Sequencing (WGS)

DefinitionTechnique that determines the sequence of all nucleotides in an individual's entire DNA (coding and non-coding regions).

RoleWGS may be considered when WES or targeted panels are nondiagnostic and when broader genomic context is needed.

Second-wind phenomenon (McArdle disease)

TermSecond-wind phenomenon

DefinitionAn exercise-related improvement after several minutes of activity described in McArdle disease where symptoms ease as aerobic metabolism becomes predominant.

Clinical relevancePresence of the second-wind phenomenon supports targeted evaluation for glycogen storage disorders such as McArdle disease and may guide biochemical and genetic testing.

Acylcarnitine analysis

TermAcylcarnitine analysis

DefinitionMass spectrometry analysis of acylcarnitines used to detect fatty acid oxidation (FAO) disorders; testing can be false-negative if performed during non-stressed periods.

Clinical useAbnormal acylcarnitine profiles support targeted genetic testing to confirm FAO disorders; if non-informative, broader panels or exome/genome may be considered.

Hereditary Spastic Paraplegia (HSP)

TermHereditary Spastic Paraplegia (HSP)

DefinitionA group of genetic diseases characterized by slowly progressive symmetrical spastic paraplegia typically due to distal axonal degeneration; over 70 genes have been identified for HSP.

Typical featuresPresentation in childhood or young adulthood with progressive lower-extremity spasticity and possible minor sensory or bladder involvement.

Congenital Muscular Dystrophy (CMD)

TermCongenital Muscular Dystrophy (CMD)

DefinitionDisorders presenting in the first two years of life with muscle weakness and hypotonia; categories include collagenopathies, merosinopathies, and dystroglycanopathies caused by multiple genes (e.g., COL6A1-3, LAMA2, FKRP).

Clinical notesCMDs often show elevated CK, characteristic muscle biopsy findings, and may have ocular/brain abnormalities depending on subtype.

Limb Girdle Muscular Dystrophy (LGMD)

TermLimb Girdle Muscular Dystrophy (LGMD)

DefinitionA heterogeneous group causing proximal (shoulder and pelvic girdle) muscle weakness with many subtypes classified by inheritance (autosomal dominant LGMD1, autosomal recessive LGMD2, etc.) and dozens of associated genes.

Clinical relevancePhenotype and inheritance pattern guide targeted gene selection; targeted NGS panels and CNV analysis improve diagnostic yield.

Heteroplasmy

TermHeteroplasmy

DefinitionPresence of multiple copies of normal and abnormal mitochondrial DNA within a cell, leading to variable phenotypic expression and challenges in genetic detection and interpretation.

Testing implicationNGS improves detection of low-level heteroplasmy in blood (detection limits ~1–10% depending on methodology and tissue); tissue or urine testing may be more informative for some mutations.

mtDNA copy number (depletion)

TermmtDNA copy number (depletion)

DefinitionA quantitative measure of mitochondrial DNA content assessed by qPCR on tissue specimens to evaluate for mtDNA depletion syndromes, which may not be detectable in blood.

Clinical useConsider mtDNA copy number testing by qPCR on tissue when depletion syndromes are suspected or when blood testing is negative despite strong clinical suspicion.

Multi-gene comprehensive neuromuscular disease test panel

TermMulti-gene comprehensive neuromuscular disease test panel

DefinitionA genetic testing panel that targets multiple neuromuscular conditions simultaneously (for example, combining muscular dystrophy and mitochondrial disease targets); this policy considers such multi-condition comprehensive panels unproven and not medically necessary when they target multiple distinct conditions.

Policy implicationPanels should be phenotype-directed (targeting a disease category) and include at least 5 genes; panels that inappropriately combine distinct condition targets risk denial and are excluded under this policy.